Compare Uranium Energy Corp (UEC) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Uranium Energy Corp vs Zimmer Biomet Holdings Inc — how do they compare? Uranium Energy Corp trades at $9.19 (market cap $4.53B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 3.7× Uranium Energy Corp's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Uranium Energy Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Uranium Energy Corp for 37 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| UEC | ZBH | |
|---|---|---|
Market Cap | $4.53B | $16.95B |
Volume | 10,888,578 | 2,505,240 |
Sector | Energy | Health |
52-Week High | $20.14 | $103.98 |
52-Week Low | $9.04 | $79.58 |
Typical Hold Time | 37 Days | 89 Days |
Enterprise Value | $4.03B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Uranium Energy (UEC) trades at $9.19, down 2.96% in the last session. The stock shows bearish technical signals with negative earnings momentum, posting losses in recent quarters despite revenue growth. The company is expanding its US uranium mining operations with two active mines, benefiting from increased government demand for domestic nuclear fuel. Analyst sentiment remains overwhelmingly positive with 87.5% buy ratings and a $16.06 consensus price target, though fundamental metrics show significant losses with a -368.62% net income margin.
UEC presents a high-risk, high-reward opportunity with strong Wall Street support but concerning financials. The bullish case hinges on nuclear energy expansion and domestic uranium demand growth, while risks include sustained operational losses, unproven production sustainability, and heavy reliance on financing activities. Current valuation appears stretched given negative profitability metrics.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.
The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
